Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Human Metabolome Technologies Inc amends consolidated mid-year outlook for FY 2015


Thursday, 12 Jun 2014 03:30am EDT 

Human Metabolome Technologies Inc:Says the company affirmed the consolidated mid-year outlook for revenue at 242 million yen for FY ending March 2015.Operating profit forecast decreased to a loss of 164 million yen from a loss of 148 million yen.Ordinary profit forecast decreased to a loss of 163 million yen from a loss of 144 million yen.Net profit forecast decreased to a loss of 161 million yen from a loss of 142 million yen.Earnings per share decreased to a loss of 30.66 yen from a loss of 27.62 yen.Comments that increased research and development funds for liver disease diagnosis kit development and increased maintenance expenses are the main reasons for the forecast.